Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act

被引:16
|
作者
Webb, Nicholas E. [1 ]
Wood, David M. [1 ,2 ]
Greene, Shaun L. [1 ,3 ]
Hunter, Laura J. [1 ]
Archer, John R. H. [1 ,2 ]
Dines, Alison M. [1 ]
Dargan, Paul I. [1 ,2 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Dept Clin Toxicol, London, England
[2] Kings Coll London, Fac Life Sci & Med, London, England
[3] Austin Hlth, Dept Clin Toxicol, Melbourne, Vic, Australia
关键词
Emergency Department; new psychoactive substances; cathinones; synthetic cannabinoids; legislation; RECREATIONAL DRUG TOXICITY; CANNABINOID RECEPTOR AGONISTS; DATA-COLLECTION; IMPACT; CONFIRMATION; MEPHEDRONE; MARKET;
D O I
10.1080/15563650.2018.1494277
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Objectives: In May 2016, the Psychoactive Substances Act (PSA) came into effect in UK making it an offence to produce or supply new psychoactive substances (NPS). The aim of this study was to determine whether this was associated with a change in Emergency Department (ED) presentations with acute NPS toxicity. Method: ED presentations to our inner-city hospital in London, UK, with acute NPS toxicity in the 12 months before and after the PSA introduction [June 2015-May 2016 (2015/2016) and June 2016-May 2017 (2016/2017)] were obtained from our database. The following data were extracted: (i) demographics; (ii) NPS(s) self-reported [categorized as synthetic cannabinoids (SC), cathinones, and "other NPS")]; and (iii) month of presentation. Results: There were 1884 presentations with recreational drug toxicity, 447 (23.7%) involved NPS. There was no difference in the overall proportion of presentations involving an NPS in 2015/2016 [n = 196 (22.3%)] and 2016/2017 [251 (24.9%); (p = .48)]. There were a mean +/- SD of 16.3 +/- 3.7 NPS-related presentations per month in 2015/2016 and 20.9 +/- 9.2 in 2016/2017; there was no significant change in overall monthly NPS-related presentations between these periods (p = .15). However, mean +/- SD monthly SC-related presentations increased from 2015/2016 (5.9 +/- 2.5) to 2016/2017 (17 +/- 9.8); p = .004. Mean monthly cathinone-related presentations decreased from 2015/2016 (8.8 +/- 4.2) to 2016/2017 (3.8 +/- 2.7); p = .001. There was no significant change in monthly mean "other NPS" presentations from 2015/2016 (1.8 +/- 2.2) to 2016/2017 (0.5 +/- 0.8); p = .062. Between 2015/2016 and 2016/2017, SCs as a proportion of NPS-related presentations increased (r = .90) whilst cathinones decreased (r = -0.82). Conclusion: NPS present front-line health services with unique challenges, and the PSA 2016 represents a major legislative effort in UK to limit their availability and supply. The burden of NPS use on this inner-city ED remains large 12 months after this legislation has come into force, with evolving patterns of NPS use.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 50 条
  • [1] Impact of the UK Psychoactive Substances Act 2016 on Emergency Department presentations related to synthetic cannabinoid receptor agonists (SCRAs), cathinones and other new psychoactive substances
    Webb, Nicholas E.
    Wood, David M.
    Archer, John R. H.
    Dines, Alison
    Dargan, Paul I.
    [J]. CLINICAL TOXICOLOGY, 2018, 56 (06) : 456 - 456
  • [2] Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series
    Evangelia Liakoni
    Patrick C. Dolder
    Katharina M. Rentsch
    Matthias E. Liechti
    [J]. BMC Pharmacology and Toxicology, 17
  • [3] Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series
    Liakoni, Evangelia
    Dolder, Patrick C.
    Rentsch, Katharina M.
    Liechti, Matthias E.
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2016, 17
  • [4] Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances
    Wood, D.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S541 - S541
  • [5] Novel Psychoactive Substances: How to Understand the Acute Toxicity Associated With the Use of These Substances
    Wood, David M.
    Dargan, Paul I.
    [J]. THERAPEUTIC DRUG MONITORING, 2012, 34 (04) : 363 - 367
  • [6] Understanding the UK Psychoactive Substances Act
    Hill, Raymond G.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (03) : 499 - 504
  • [7] Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances
    Deligianni, Elena
    Daniel, Omari J.
    Corkery, John M.
    Schifano, Fabrizio
    Lione, Lisa A.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (03) : 505 - 516
  • [8] Emergency Department presentations with illicit drugs associated with problematic drug use (iPDU) toxicity are not commonly associated with co-use of new psychoactive substances (NPS)
    De La Rue, Luke C.
    Wood, David M.
    Dines, Alison M.
    Hovda, Knut Erik
    Heyerdahl, Fridtjof
    Yates, Christopher
    Giraudon, Isabelle
    Dargan, Paul I.
    [J]. CLINICAL TOXICOLOGY, 2017, 55 (05) : 478 - 479
  • [9] Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service. A time series analysis
    Al-Banaa, I
    Hawkins, L.
    Hill, S. L.
    Lupton, D. J.
    Jackson, G.
    Sandilands, E. A.
    Bradberry, S. M.
    Thompson, J. P.
    Rushton, S.
    Thomas, S. H. L.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 77
  • [10] Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016
    Deen, Adrian A.
    Claridge, Hugh
    Treble, Richard D.
    Hamnett, Hilary J.
    Copeland, Caroline S.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (11) : 1315 - 1323